tiprankstipranks
Advertisement
Advertisement

KLRS Stock Latest News

Why Is Kalaris Therapeutics (KLRS) Up Today?
Market NewsWhy Is Kalaris Therapeutics (KLRS) Up Today?
44m ago
KLRS
Analyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability
PremiumRatings
Analyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability
2h ago
KLRS
Kalaris Therapeutics reports positive Phase 1a TH103 results
PremiumCompany Announcements
Kalaris Therapeutics reports positive Phase 1a TH103 results
6h ago
8K
KLRS
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
PremiumThe Fly
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
7h ago
KLRS
Kalaris Therapeutics Announces Board and Audit Committee Changes
PremiumCompany Announcements
Kalaris Therapeutics Announces Board and Audit Committee Changes
11d ago
8K
KLRS
Kalaris Therapeutics initiated with a Buy at TD Cowen
PremiumThe FlyKalaris Therapeutics initiated with a Buy at TD Cowen
1M ago
KLRS
Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market
Premium
Ratings
Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market
1M ago
KLRS
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor
Premium
Company Announcements
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor
1M ago
8K
KLRS
CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
PremiumMarket News
CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
2M ago
CRWV
CVBF
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
2M ago
KLRS
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
2M ago
TM
AIZ
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
PremiumThe Fly
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
2M ago
KLRS
Kalaris Therapeutics initiated with an Outperform at Wedbush
PremiumThe FlyKalaris Therapeutics initiated with an Outperform at Wedbush
2M ago
KLRS
Kalaris Therapeutics price target lowered to $25 from $26 at Citizens
Premium
The Fly
Kalaris Therapeutics price target lowered to $25 from $26 at Citizens
2M ago
KLRS
Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)
Premium
The Fly
Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)
2M ago
KLRS
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe Fly
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
3M ago
KLRS
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
PremiumCompany Announcements
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
3M ago
8K
KLRS
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
PremiumRatings
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
4M ago
KLRS
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
PremiumThe Fly
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
4M ago
KLRS
Kalaris Therapeutics sees cash runway into 4Q27
PremiumThe FlyKalaris Therapeutics sees cash runway into 4Q27
4M ago
KLRS
Kalaris Updates TH103 Strategy and Highlights Cash Runway
Premium
Company Announcements
Kalaris Updates TH103 Strategy and Highlights Cash Runway
4M ago
8K
KLRS
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
Premium
Weekend Updates
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
7M ago
BRO
ANNX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >